Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Top Cited Papers
Open Access
- 13 November 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1), 1-9
- https://doi.org/10.1186/s40425-019-0800-0
Abstract
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. Patients with metastatic or unresectable UM treated with ipilimumab in combination with a PD-1 inhibitor were collected from 16 German skin cancer centers. Patient records of 64 cases were analyzed for response, progression-free survival (PFS), overall survival (OS), and safety. Clinical parameters and serum biomarkers associated with OS and treatment response were determined with Cox regression modelling and logistic regression. The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and partial response, respectively. The median duration of response was 25.5 months (range 9.0–65.0). Stable disease was achieved in 21.9%, resulting in a disease control rate of 37.5% with a median duration of the clinical benefit of 28.0 months (range 7.0–65.0). The median PFS was 3.0 months (95% CI 2.4–3.6). The median OS was estimated to 16.1 months (95% CI 12.9–19.3). Regarding safety, 39.1% of treated patients experienced a severe, treatment-related adverse event according to the CTCAE criteria (grade 3: 37.5%; grade 4: 1.6%). The most common toxicities were colitis (20.3%), hepatitis (20.3%), thyreoiditis (15.6%), and hypophysitis (7.8%). A poor ECOG performance status was an independent risk factor for decreased OS (p = 0.007). The tolerability of the combined checkpoint blockade in UM may possibly be better than in trials on cutaneous melanoma. This study implies that combined checkpoint blockade represents the hitherto most effective treatment option available for metastatic UM available outside of clinical trials.This publication has 29 references indexed in Scilit:
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClinical Cancer Research, 2016
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabClinical Cancer Research, 2016
- The use of pembrolizumab for the treatment of metastatic uveal melanomaMelanoma Research, 2016
- Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanomaOncoImmunology, 2016
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treatment Reviews, 2016
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaJournal of Translational Medicine, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in EuropeEuropean Journal of Cancer, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009